Skip to content
MarketScale
Demo
‹ Back to IndustriesSciences

Legionella Risk Management

Chem-Aqua has the capabilities to help customers with cooling tower regulations and Water Management Plans.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share

Key takeaways

01

Chem-Aqua has the capabilities to help customers with cooling tower regulations and Water Management Plans.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Chem-Aqua has the capabilities to help customers with cooling tower regulations and Water Management Plans.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics signs $262M manufacturing deal through 2033, pushing longer CDMO bookings

Samsung Biologics disclosed a $262 million biologics manufacturing contract running through 2033. The work will be produced at Songdo, South Korea. The deal lifts Samsung Biologics’ cumulative contract value above $21.9 billion, per BioPharm International.

  • 01Duration is the headline: Samsung Biologics’ new $262 million contract with an unnamed European pharma company runs through Dec. 31, 2033, a long-dated commitment for the Songdo site (per BioPharm International).
  • 02CDMO selection is drifting from “price per batch” to “operating model”: Samsung Biologics executives have framed CDMOs as extensions of sponsor operations, which raises expectations for transparency, change control, and schedule flexibility (per BioPharm International).

Sep 13, 2026

Robotic Systems Emerge for Cell and Gene Therapy Manufacturing

Robotic Systems Emerge for Cell and Gene Therapy Manufacturing

A September 2024 Cytotherapy paper describes a robotic cluster designed to automate manual steps in cell therapy manufacturing. Additional reviews published in 2019 and 2026, along with commentary from Genetic Engineering and Biotechnology News, discuss automation and AI as tools being explored for the cell and gene therapy manufacturing sector.

  • 01A robotic cluster combining a robotic arm with customized modules can handle standard cell therapy equipment (incubators, bioreactors, reagent bags) without requiring entirely new manufacturing platforms.
  • 02The system produced human CD8+ T cells with cell yields, viability and identity comparable to manual cultures while maintaining sterility, according to the Cytotherapy paper.
  • 03Manufacturing automation and AI are cited in industry analysis as potential solutions to skilled labor shortages and production scaling challenges, particularly for allogeneic therapies manufactured at larger scale.

Sep 13, 2026

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's Biopharma AI Value Estimates Come With a Timing Catch

Deloitte's 2024 report, covered by TechTarget in April 2024, estimated that a top-10 biopharma company could capture $5-7 billion in peak AI value over five years, with about 90% concentrated in R&D, manufacturing/supply chain, and commercial functions. McKinsey reported in November 2025 that despite rising AI investment, pharma companies have not yet seen shorter development timelines or better clinical success rates.

  • 01Deloitte estimates $5–7B peak AI value for top-10 biopharma firms over five years, with cost reductions appearing in 1–2 quarters and revenue gains taking 3–4 quarters.
  • 02McKinsey found pharma companies have not yet achieved shorter drug development timelines or improved preclinical and clinical success rates despite increased AI spending.
  • 03AI systems used in manufacturing, supply chain, and R&D functions may require validation under existing regulated systems frameworks like GAMP.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Sciences

Sciences hubMore expert Sciences coverage.Explore →Executive Thought LeadershipPut researchers on the record.Explore →FinThriveComplex topics, made clear.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512